Kari Vastag

672 total citations
14 papers, 477 citations indexed

About

Kari Vastag is a scholar working on Infectious Diseases, Virology and Oncology. According to data from OpenAlex, Kari Vastag has authored 14 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 7 papers in Virology and 6 papers in Oncology. Recurrent topics in Kari Vastag's work include HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (7 papers) and Peptidase Inhibition and Analysis (4 papers). Kari Vastag is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (7 papers) and Peptidase Inhibition and Analysis (4 papers). Kari Vastag collaborates with scholars based in United States. Kari Vastag's co-authors include Jiunn H. Lin, Joy A. Nishime, Masato Chiba, Dražen Ostović, Suresh K. Balani, Gloria Y. Kwei, Sidney D. Lewis, Elizabeth A. Lyle, Adel M. Naylor-Olsen and Maria T. Stranieri and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and Biochemical Pharmacology.

In The Last Decade

Kari Vastag

14 papers receiving 445 citations

Peers

Kari Vastag

VIROL

ONCOL

Lianhong Xu United States

Gary D. Bowers United States

Celia D’Arienzo United States

Eve‐Irene Lepist United States

I‐Wu Chen United States

Lewis J. Klunk United States

Gerry Rhodes United States

R Cvetković New Zealand

David A. Betebenner United States

Michael Kukulka United States

Lianhong Xu United States

Kari Vastag

231 ×1.3

270 ×1.8

146 ×1.2

VIROL

378 ×3.3

92 ×0.9

ONCOL

Citations per year, relative to Kari Vastag Kari Vastag (= 1×) peers Lianhong Xu

Countries citing papers authored by Kari Vastag

Since Specialization

Citations

This map shows the geographic impact of Kari Vastag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kari Vastag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kari Vastag more than expected).

Fields of papers citing papers by Kari Vastag

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kari Vastag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kari Vastag. The network helps show where Kari Vastag may publish in the future.

Co-authorship network of co-authors of Kari Vastag

This figure shows the co-authorship network connecting the top 25 collaborators of Kari Vastag. A scholar is included among the top collaborators of Kari Vastag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kari Vastag. Kari Vastag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Coburn, Craig A., Peter Williams, Carl F. Homnick, et al.. (2000). Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 10(10). 1069–1072. 19 indexed citations

Chiba, Masato, Joy A. Nishime, I‐Wu Chen, et al.. (1998). Metabolite–P450 Complex Formation by Methylenedioxyphenyl HIV Protease Inhibitors in Rat and Human Liver Microsomes. Biochemical Pharmacology. 56(2). 223–230. 8 indexed citations

Sanderson, Philip E.J., Bruce D. Dorsey, Colleen M. McDonough, et al.. (1998). L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorganic & Medicinal Chemistry Letters. 8(7). 817–822. 51 indexed citations

Isaacs, Richard C.A., Philip E.J. Sanderson, Elizabeth Baskin, et al.. (1998). C6 Modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption. Bioorganic & Medicinal Chemistry Letters. 8(13). 1719–1724. 19 indexed citations

Brady, Stephen F., Kenneth J. Stauffer, William C. Lumma, et al.. (1998). Discovery and Development of the Novel Potent Orally Active Thrombin Inhibitor N-(9-Hydroxy-9-fluorenecarboxy)prolyl trans-4-Aminocyclohexylmethyl Amide (L-372,460): Coapplication of Structure-Based Design and Rapid Multiple Analogue Synthesis on Solid Support. Journal of Medicinal Chemistry. 41(3). 401–406. 59 indexed citations

Lin, Jiunn H., et al.. (1996). Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence.. Drug Metabolism and Disposition. 24(12). 1298–1306. 44 indexed citations

Lin, Jiunn H., Masato Chiba, Suresh K. Balani, et al.. (1996). Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.. Drug Metabolism and Disposition. 24(10). 1111–1120. 130 indexed citations

Vastag, Kari, et al.. (1995). High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. Journal of Chromatography B Biomedical Sciences and Applications. 672(1). 111–117. 23 indexed citations

Lin, Jiunn H., et al.. (1995). pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.. Drug Metabolism and Disposition. 23(7). 730–735. 72 indexed citations

10.

Lin, Jiunn H., Masato Chiba, Kari Vastag, et al.. (1995). Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys.. Journal of Pharmacology and Experimental Therapeutics. 274(1). 264–269. 19 indexed citations

11.

Zartman, C. Blair, Joseph P. Vacca, Stuart R. Michelson, et al.. (1995). Substituted alkylpyridines as P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors: Improved pharmacokinetic profiles. Bioorganic & Medicinal Chemistry Letters. 5(19). 2239–2244. 2 indexed citations

12.

Guare, James P., Stuart R. Michelson, Paul L. Darke, et al.. (1995). Thiophene derivatives as extremely high affinity P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 5(2). 185–190. 6 indexed citations

13.

Evans, B., Kevin F. Gilbert, Joseph P. Vacca, et al.. (1995). Cycloalkylpiperazines as HIV-1 protease inhibitors: enhanced oral absorption. Bioorganic & Medicinal Chemistry Letters. 5(22). 2707–2712. 17 indexed citations

14.

Vacca, Joseph P., James P. Guare, Stuart R. Michelson, et al.. (1994). A new hydroxyethylamine class of HIV-1 protease inhibitors with high antiviral potency and oral bioavailability. Bioorganic & Medicinal Chemistry Letters. 4(19). 2273–2278. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact